Many MDM2 splicing variants have been described in a variety of malignancies, including ovarian cancer [13], breast cancer [14], non-small cell lung cancer [15], and liposarcoma [16], revealing the complexity of the MDM2 and p53 feedback loop. This evidence concerns the gene TP53 and liposarcoma.